| Authors: |
Gurwith M; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA., Condit RC; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA., Excler JL; International Vaccine Institute, Seoul, Republic of Korea., Robertson JS; Independent Adviser, United Kingdom., Kim D; Janssen Pharmaceuticals, Titusville, NJ, USA., Fast PE; International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Paolo Alto, CA, USA., Drew S; Independent Adviser, USA., Wood D; Independent Adviser, United Kingdom., Klug B; Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany., Whelan M; Project Leader, CEPI, UK., Mallett Moore T; Sanofi Pasteur, Swiftwater, PA, USA., Khuri-Bulos N; University of Jordan, Amman, Jordan., Smith ER; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA. Electronic address: bc-coordinator@taskforce.org., Chen RT; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA., Kochhar S; Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA, USA. |
